Cargando…
Enhancing Targeted Therapy in Breast Cancer by Ultrasound-Responsive Nanocarriers
Currently, the response to cancer treatments is highly variable, and severe side effects and toxicity are experienced by patients receiving high doses of chemotherapy, such as those diagnosed with triple-negative breast cancer. The main goal of researchers and clinicians is to develop new effective...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053544/ https://www.ncbi.nlm.nih.gov/pubmed/36982548 http://dx.doi.org/10.3390/ijms24065474 |
_version_ | 1785015438859567104 |
---|---|
author | Edwards, Isaiah A. De Carlo, Flavia Sitta, Juliana Varner, William Howard, Candace M. Claudio, Pier Paolo |
author_facet | Edwards, Isaiah A. De Carlo, Flavia Sitta, Juliana Varner, William Howard, Candace M. Claudio, Pier Paolo |
author_sort | Edwards, Isaiah A. |
collection | PubMed |
description | Currently, the response to cancer treatments is highly variable, and severe side effects and toxicity are experienced by patients receiving high doses of chemotherapy, such as those diagnosed with triple-negative breast cancer. The main goal of researchers and clinicians is to develop new effective treatments that will be able to specifically target and kill tumor cells by employing the minimum doses of drugs exerting a therapeutic effect. Despite the development of new formulations that overall can increase the drugs’ pharmacokinetics, and that are specifically designed to bind overexpressed molecules on cancer cells and achieve active targeting of the tumor, the desired clinical outcome has not been reached yet. In this review, we will discuss the current classification and standard of care for breast cancer, the application of nanomedicine, and ultrasound-responsive biocompatible carriers (micro/nanobubbles, liposomes, micelles, polymeric nanoparticles, and nanodroplets/nanoemulsions) employed in preclinical studies to target and enhance the delivery of drugs and genes to breast cancer. |
format | Online Article Text |
id | pubmed-10053544 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100535442023-03-30 Enhancing Targeted Therapy in Breast Cancer by Ultrasound-Responsive Nanocarriers Edwards, Isaiah A. De Carlo, Flavia Sitta, Juliana Varner, William Howard, Candace M. Claudio, Pier Paolo Int J Mol Sci Review Currently, the response to cancer treatments is highly variable, and severe side effects and toxicity are experienced by patients receiving high doses of chemotherapy, such as those diagnosed with triple-negative breast cancer. The main goal of researchers and clinicians is to develop new effective treatments that will be able to specifically target and kill tumor cells by employing the minimum doses of drugs exerting a therapeutic effect. Despite the development of new formulations that overall can increase the drugs’ pharmacokinetics, and that are specifically designed to bind overexpressed molecules on cancer cells and achieve active targeting of the tumor, the desired clinical outcome has not been reached yet. In this review, we will discuss the current classification and standard of care for breast cancer, the application of nanomedicine, and ultrasound-responsive biocompatible carriers (micro/nanobubbles, liposomes, micelles, polymeric nanoparticles, and nanodroplets/nanoemulsions) employed in preclinical studies to target and enhance the delivery of drugs and genes to breast cancer. MDPI 2023-03-13 /pmc/articles/PMC10053544/ /pubmed/36982548 http://dx.doi.org/10.3390/ijms24065474 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Edwards, Isaiah A. De Carlo, Flavia Sitta, Juliana Varner, William Howard, Candace M. Claudio, Pier Paolo Enhancing Targeted Therapy in Breast Cancer by Ultrasound-Responsive Nanocarriers |
title | Enhancing Targeted Therapy in Breast Cancer by Ultrasound-Responsive Nanocarriers |
title_full | Enhancing Targeted Therapy in Breast Cancer by Ultrasound-Responsive Nanocarriers |
title_fullStr | Enhancing Targeted Therapy in Breast Cancer by Ultrasound-Responsive Nanocarriers |
title_full_unstemmed | Enhancing Targeted Therapy in Breast Cancer by Ultrasound-Responsive Nanocarriers |
title_short | Enhancing Targeted Therapy in Breast Cancer by Ultrasound-Responsive Nanocarriers |
title_sort | enhancing targeted therapy in breast cancer by ultrasound-responsive nanocarriers |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10053544/ https://www.ncbi.nlm.nih.gov/pubmed/36982548 http://dx.doi.org/10.3390/ijms24065474 |
work_keys_str_mv | AT edwardsisaiaha enhancingtargetedtherapyinbreastcancerbyultrasoundresponsivenanocarriers AT decarloflavia enhancingtargetedtherapyinbreastcancerbyultrasoundresponsivenanocarriers AT sittajuliana enhancingtargetedtherapyinbreastcancerbyultrasoundresponsivenanocarriers AT varnerwilliam enhancingtargetedtherapyinbreastcancerbyultrasoundresponsivenanocarriers AT howardcandacem enhancingtargetedtherapyinbreastcancerbyultrasoundresponsivenanocarriers AT claudiopierpaolo enhancingtargetedtherapyinbreastcancerbyultrasoundresponsivenanocarriers |